首页 | 本学科首页   官方微博 | 高级检索  
     


The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Authors:Michael A Becker  H Ralph Schumacher  Luis R Espinoza  Alvin F Wells  Patricia MacDonald  Eric Lloyd  Christopher Lademacher
Affiliation:(1) The University of Chicago Pritzker School of Medicine, MC0930, University of Chicago Medical Center, 5841 S. Maryland Avenue, Chicago, IL 60637, USA;(2) VA Medical Center, University of Pennsylvania and VA Medical Center, 151K University and Woodland Avenues, Philadelphia, PA 19104, USA;(3) Rheumatology, Louisiana State University Health Sciences Center, 2820 Napoleon Avenue, Suite 890, New Orleans, LA 70115, USA;(4) Rosalind Franklin University of Medicine & Science, 1457 Indian Grass Lane, Grays Lake, IL 60030, USA;(5) Takeda Global Research & Development Center Inc., 675 Field Drive, Lake Forest, IL 60045, USA;(6) Astellas Pharma Global Development Inc., 3 Parkway North, Deerfield, IL 60015, USA
Abstract:

Introduction  

The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) ≥ 8.0 mg/dL in a six-month trial.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号